Literature DB >> 6356277

Adverse effects of rifampin.

J Grosset, S Leventis.   

Abstract

Rifampin has proved to be a valuable antibiotic with relatively few major adverse effects. Its toxicity is predominantly hepatic and immunoallergic in character. While hepatic toxicity is dose related and has been observed mainly in patients with underlying liver disease, the immunoallergic effects are usually associated with intermittent or prolonged therapy. These immunoallergic effects may be minor (a cutaneous, gastrointestinal, or influenzalike syndrome) or major (hemolytic anemia, shock, or acute renal failure).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356277     DOI: 10.1093/clinids/5.supplement_3.s440

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  35 in total

Review 1.  Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin.

Authors:  Thomas C Havey; Christine Cserti-Gazdewich; Michelle Sholzberg; Jay S Keystone; Wayne L Gold
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

3.  CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.

Authors:  Gillian L Beamer; Joshua Cyktor; David K Flaherty; Paul C Stromberg; Bridget Carruthers; Joanne Turner
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

Review 4.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.

Authors:  A H Diacon; R F Patientia; A Venter; P D van Helden; P J Smith; H McIlleron; J S Maritz; P R Donald
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

6.  Liver and pancreatic injury induced by antituberculous therapy.

Authors:  M Markov; K Patel; A Raeesy; A Bant; D H Van Thiel; A Nadir
Journal:  Dig Dis Sci       Date:  2007-02-15       Impact factor: 3.199

Review 7.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

8.  Hepatobiliary quiz-6 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-06

9.  Intraocular penetration of rifampin after oral administration.

Authors:  K W Wong; D J D'Amico; B S Oum; P A Baker; K R Kenyon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

10.  Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Authors:  Kelly E Dooley; Radojka M Savic; Jeong-Gun Park; Yoninah Cramer; Richard Hafner; Evelyn Hogg; Jennifer Janik; Mark A Marzinke; Kristine Patterson; Constance A Benson; Laura Hovind; Susan E Dorman; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.